1st Quarter - Report

FEROX STRATEGIES for VIATRIS INC

Period 1st Quarter 2026 Filed Apr 17, 2026 Signed by Cristina Antelo

Official filing
Firm
FEROX STRATEGIES
Client
VIATRIS INC
Income
$70,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).

LobbyistCovered position, as disclosed
CRISTINA ANTELO —
DEBRA DIXON —
ZACHARY BENJAMIN FRIEND —
MICHAEL TAGGART —
MARK WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 1071 (119th)

Trade (domestic/foreign) TRD

Trade issues related to generic medicines.

LobbyistCovered position, as disclosed
MARK WILLIAMS —

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.